Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Pozycja w akcjach #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Cena akcji
$0.01292666
Ostatnia synchronizacja: 2025-04-08
Kapitalizacja rynkowa
$157.54K
Zmiana (1 dzień)
6.84%
Zmiana (1 rok)
0.00%
Kraj
GB
Handel Synairgen plc (SNG)

Kategoria

Historia ceny akcji dla Synairgen plc (SNG)
Najwyższa cena zamknięcia: $0.01 dnia 2025-04-01

Najniższa cena zamknięcia: $2.04 dnia 2004-10-01
Historia cen akcji firmy Synairgen plc od 2004 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2025 -66.26%
2024 -44.21%
2023 -52.93%
2022 -92.61%
2021 77.16%
2020 1,567.16%
2019 -48.13%
2018 14.84%
2017 -14.89%
2016 -49.84%
2015 -35.02%
2014 -37.63%
2013 15.10%
2012 50.92%
2011 14.84%
2010 -28.85%
2009 88.33%
2008 -77.12%
2007 -24.86%
2006 -99.32%
2005 209.00%
2004 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$517.18 30.63%
US
$857.76 32.66%
NL
$744.96 8.94%
CH
$1.08K -6.68%
KR
$259.89 16.65%
BE